Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Apr 18;30(4):161–164. doi: 10.1002/clc.20003

Metabolic syndrome in African Americans: Implications for preventing coronary heart disease

Luther T Clark 1,✉, Fadi El‐Atat 1
PMCID: PMC6653775  PMID: 17443653

Abstract

The metabolic syndrome represents a specific clustering of cardiovascular risk factors in the same individual (abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, insulin resistance, a prothrombotic state, and a proinflammatory state). Almost 50 million American adults (about one in four) have the metabolic syndrome, which puts them at increased risk for the development of diabetes mellitus and cardiovascular disease. African Americans, especially African‐American women, have a high prevalence of the metabolic syndrome. This is attributable mainly to the disproportionate occurrence in African Americans of elevated blood pressure, obesity, and diabetes. Management of the metabolic syndrome consists primarily of modification or reversal of the root causes (overweight/obesity and physical inactivity) and therapy to reduce or control the risk factors. Although all components of the metabolic syndrome should be addressed, optimal control of atherogenic dyslipidemia and elevated blood pressure may reduce cardiovascular risk by more than 80%. Copyright © 2007 Wiley Periodicals, Inc.

Keywords: African Americans, cardiovascular disease, metabolic syndrome

Full Text

The Full Text of this article is available as a PDF (252.0 KB).

REFERENCES

  • 1. American Heart Association : Heart Disease and Stroke Statistics—2005 Update. Dallas, Texas: American Heart Association, 2005.
  • 2. Clark LT, Ferdinand KC, Flack JM, Gavin JR III, Hall WD, et al.: Coronary heart disease in African Americans. Heart Dis 2001;3:97–108 [DOI] [PubMed] [Google Scholar]
  • 3. The Expert Panel : Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final report. Circulation 2002;106:3146–3421 [PubMed] [Google Scholar]
  • 4. Hutchinson RG, Watson RL, Davis CE, Barnes R, Brown S, et al.: Racial differences in risk factors for atherosclerosis: The ARIC Study. Angiology 1997;48:279–290 [DOI] [PubMed] [Google Scholar]
  • 5. Hall WD, Clark LT, Wenger NK, Wright JT Jr, Kumanyika SK, et al.: The metabolic syndrome in African Americans: A review. Ethn Dis 2003; 13:414–428 [PubMed] [Google Scholar]
  • 6. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutritional Examination Survey. J Am Med Assoc 2002;287:356–359 [DOI] [PubMed] [Google Scholar]
  • 7. Smith SC Jr, Clark LT, Cooper RS, Daniels SR, Kumanyika SK, et al.: Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: Report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group. Circulation 2005;111:e134–e139 [DOI] [PubMed] [Google Scholar]
  • 8. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al.: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–2752 [DOI] [PubMed] [Google Scholar]
  • 9.Lakka H‐M, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle‐aged men. J Am Med Assoc 2002;288:2709–2716 [DOI] [PubMed] [Google Scholar]
  • 10. Ridker PM, Buring JE, Cook NR, Rifai N: C‐reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8‐year follow‐up of 14,719 initially healthy American women. Circulation 2003;107:391–397 [DOI] [PubMed] [Google Scholar]
  • 11. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP: National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all‐cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251–1257 [DOI] [PubMed] [Google Scholar]
  • 12. Isomaa B, Almgren P, Tuomi T, Fors´n B, Lahti K, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–689 [DOI] [PubMed] [Google Scholar]
  • 14. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999–2000. J Am Med Assoc 2002;288:1723–1727 [DOI] [PubMed] [Google Scholar]
  • 15. Okosun IS, Choi ST, Boltri JM, Parish DC, Chandra KMD, et al.: Trends of abdominal adiposity in white, black, and Mexican‐American adults, 1988 to 2000. Obes Res 2003;11:1010–1017 [DOI] [PubMed] [Google Scholar]
  • 16. Despres JP: The insulin resistance–dyslipidemic syndrome of visceral obesity: Effect on patients' risk. Obes Res 1998;6(suppl 1):8S–17S [DOI] [PubMed] [Google Scholar]
  • 17. Haffner SM, D' Agostino R Jr, Goff D, Howard B, Festa A, et al.: LDL size in African Americans, Hispanics, and non‐Hispanic whites: The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol 1999;19:2234–2240 [DOI] [PubMed] [Google Scholar]
  • 18. Jones DW, Chambless LE, Folsom AR, Heiss G, Hutchinson RG, et al.: Risk factors for coronary heart disease in African Americans: The Atherosclerosis Risk in Communities Study, 1987–1997. Arch Intern Med 2002;162:2565–2571 [DOI] [PubMed] [Google Scholar]
  • 19. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK: The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. J Am Med Assoc 1995;273:1592–1597 [PubMed] [Google Scholar]
  • 20. Haffner SM, D' Agostino R Jr, Saad MF, Rewers M, Mykkanen L, et al.: Increased insulin resistance and insulin secretion in nondiabetic African Americans and Hispanics compared with non‐Hispanic whites: The insulin resistance atherosclerosis study. Diabetes 1996;45:742–748 [DOI] [PubMed] [Google Scholar]
  • 21. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, et al.: Race and gender differences in C‐reactive protein levels. J Am Coll Cardiol 2005;46:464–469 [DOI] [PubMed] [Google Scholar]
  • 22.Ridker PM: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: Rationale and design of the JUPITER trial. Circulation 2003;108:2292–2297 [DOI] [PubMed] [Google Scholar]
  • 23. Folsom AR, Qamhieh HT, Flack JM, Hilner JE, Liu K, et al.: Plasma fibrinogen: Levels and correlates in young adults: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Epidemiol 1993;138:1023–1036 [DOI] [PubMed] [Google Scholar]
  • 24. Wong ND, Pio JR, Franklin SS, L' Italien GJ, Kamath TV, et al.: Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003;91:1421–1426 [DOI] [PubMed] [Google Scholar]
  • 25. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB Jr, Clark LT, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110: 227–239 [DOI] [PubMed] [Google Scholar]
  • 26.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT). J Am Med Assoc 2002;288:2998–3007 [DOI] [PubMed] [Google Scholar]
  • 27. Ferdinand KC, Clark LT, Watson KE, Neal RC, Brown CD, et al.: for the ARIES Study Group: Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African‐American patients in a six‐week trial. Am J Cardiol 2006;97:229–235 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES